Press release
Primary Biliary Cholangitis Pipeline Insight 2025: FXR Agonists, PPAR Modulators, and Novel Anti-Fibrotics Drive Development | DelveInsight
Primary Biliary Cholangitis Pipeline
Key clinical-stage candidates include Seladelpar by CymaBay Therapeutics, a PPAR-delta agonist that has demonstrated significant improvements in alkaline phosphatase levels and symptom relief. Genfit's Elafibranor, a dual PPAR-alpha/delta agonist, is also being evaluated for anti-fibrotic and cholestatic effects. Additionally, Intercept Pharmaceuticals is advancing new-generation FXR agonists aimed at reducing pruritus and improving liver enzyme normalization. Early-phase programs from Mirum Pharmaceuticals and Albireo Pharma are exploring ASBT inhibitors and novel bile acid analogs.
With growing clinical focus on patient-reported outcomes, fatigue and itching-two of PBC's most debilitating symptoms-are becoming endpoints alongside biochemical markers. Regulatory bodies, including the FDA and EMA, have shown increasing support through priority review pathways and conditional approvals, recognizing the need for long-term liver preservation strategies. As more therapies reach late-stage development, the PBC pipeline is poised to offer patients a better quality of life and liver-related outcomes.
Interested in learning more about the current treatment landscape and the key drivers shaping the primary biliary cholangitis pipeline? Click here: https://www.delveinsight.com/report-store/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Primary Biliary Cholangitis Pipeline Report
• DelveInsight's primary biliary cholangitis pipeline analysis depicts a strong space with 20+ active players working to develop 25+ pipeline drugs for primary biliary cholangitis treatment.
• The leading primary biliary cholangitis companies include Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Dr Falk Pharma, Mirum Pharmaceuticals, GlaxoSmithKline, and others are evaluating their lead assets to improve the primary biliary cholangitis treatment landscape.
• Key primary biliary cholangitis pipeline therapies in various stages of development include Saroglitazar Magnesium, Setanaxib, HPG-1860, Norucholic acid, RhuDex, Volixibat, Linerixibat, and others.
• In June 2025, GSK plc (LSE/NYSE: GSK) announced the FDA has accepted the NDA for linerixibat, an IBAT inhibitor for treating cholestatic pruritus in primary biliary cholangitis (PBC). The PDUFA goal date is March 24, 2026.
• In January 2025, Cour Pharmaceuticals received orphan drug designation from the FDA for CNP-104, a treatment for primary biliary cholangitis (PBC).
• In December 2024, Gilead Sciences announced that the FDA granted accelerated approval for LIVDELZI (seladelpar) to treat primary biliary cholangitis (PBC). The drug is approved for use in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA or as a monotherapy for patients who cannot tolerate UDCA. However, Livdelzi is not recommended for individuals with or who develop decompensated cirrhosis.
Request a sample and discover the recent breakthroughs happening in the primary biliary cholangitis pipeline landscape at https://www.delveinsight.com/report-store/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Primary Biliary Cholangitis Overview
Primary Biliary Cholangitis (PBC) is a chronic, progressive autoimmune liver disease characterized by the gradual destruction of the small bile ducts within the liver. This damage leads to impaired bile flow (cholestasis), causing bile to accumulate and eventually resulting in liver inflammation, fibrosis, and potentially cirrhosis if untreated. PBC primarily affects middle-aged women and is often diagnosed through blood tests detecting specific antibodies, elevated liver enzymes, and imaging studies.
Symptoms of PBC can include fatigue, itching, dry eyes and mouth, and jaundice in advanced stages. While the exact cause is unknown, it is believed to involve a combination of genetic and environmental factors triggering an autoimmune response. Treatment focuses on slowing disease progression and managing symptoms, with ursodeoxycholic acid (UDCA) being the first-line therapy. For patients who do not respond to UDCA, additional medications like obeticholic acid may be used, and liver transplantation is considered in advanced cases.
Find out more about primary biliary cholangitis medication at https://www.delveinsight.com/report-store/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Primary Biliary Cholangitis Treatment Analysis: Drug Profile
Setanaxib: Calliditas Therapeutics
Setanaxib (GKT831) is a NOX1 and NOX4 inhibitor that has demonstrated anti-fibrotic effects in a Phase II clinical trial for primary biliary cholangitis (PBC), a rare liver disease. Following promising Phase II results, a Phase II/III trial for Setanaxib in PBC has been initiated. Additionally, Setanaxib is being investigated in Phase II trials led by investigators for Type 1 Diabetes with kidney disease (DKD) and idiopathic pulmonary fibrosis (IPF), a chronic lung condition characterized by fibrosis.
HPG-1860: Hepagene
HPG-1860, developed by Hepagene, is an oral drug candidate for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). It is an avermectin derivative that works by targeting the farnesoid X receptor (FXR). HPG-1860 is currently in Phase I clinical development for PBC.
Learn more about the novel and emerging primary biliary cholangitis pipeline therapies at https://www.delveinsight.com/report-store/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Primary Biliary Cholangitis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide
Scope of the Primary Biliary Cholangitis Pipeline Report
• Coverage: Global
• Key Primary Biliary Cholangitis Companies: Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Dr Falk Pharma, Mirum Pharmaceuticals, GlaxoSmithKline, and others.
• Key Primary Biliary Cholangitis Pipeline Therapies: Saroglitazar Magnesium, Setanaxib, HPG-1860, Norucholic acid, RhuDex, Volixibat, Linerixibat, and others.
To dive deep into rich insights for drugs used for primary biliary cholangitis treatment, visit: https://www.delveinsight.com/report-store/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Primary Biliary Cholangitis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Primary Biliary Cholangitis Pipeline Therapeutics
6. Primary Biliary Cholangitis Pipeline: Late-Stage Products (Phase III)
7. Primary Biliary Cholangitis Pipeline: Mid-Stage Products (Phase II)
8. Primary Biliary Cholangitis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cholangitis Pipeline Insight 2025: FXR Agonists, PPAR Modulators, and Novel Anti-Fibrotics Drive Development | DelveInsight here
News-ID: 4125173 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
